CR9491A - Delivery of tigecycline in the presence of heparin - Google Patents

Delivery of tigecycline in the presence of heparin

Info

Publication number
CR9491A
CR9491A CR9491A CR9491A CR9491A CR 9491 A CR9491 A CR 9491A CR 9491 A CR9491 A CR 9491A CR 9491 A CR9491 A CR 9491A CR 9491 A CR9491 A CR 9491A
Authority
CR
Costa Rica
Prior art keywords
tigecycline
heparin
delivery
administration
directed
Prior art date
Application number
CR9491A
Other languages
English (en)
Inventor
Stephen A Ludwing
Maja Vencl-Joncic
Pooja Gandhi
Joseph Gross
Julianna Koczone
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR9491A publication Critical patent/CR9491A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

La presente divulgacion esta dirigida a terapias de combinacion de tigeciclina y heparina y a metodos para la administracion de la tigeciclina y la heparina.
CR9491A 2005-05-06 2007-10-31 Delivery of tigecycline in the presence of heparin CR9491A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67820305P 2005-05-06 2005-05-06

Publications (1)

Publication Number Publication Date
CR9491A true CR9491A (es) 2008-02-21

Family

ID=36973003

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9491A CR9491A (es) 2005-05-06 2007-10-31 Delivery of tigecycline in the presence of heparin

Country Status (14)

Country Link
US (1) US20060251705A1 (es)
EP (1) EP1877064A2 (es)
JP (1) JP2008540431A (es)
KR (1) KR20080005599A (es)
CN (1) CN101171016A (es)
AU (1) AU2006244588A1 (es)
BR (1) BRPI0611070A2 (es)
CA (1) CA2607143A1 (es)
CR (1) CR9491A (es)
MX (1) MX2007013895A (es)
NO (1) NO20075690L (es)
RU (1) RU2007140956A (es)
WO (1) WO2006121713A2 (es)
ZA (1) ZA200709510B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102595895B1 (ko) * 2015-11-27 2023-10-31 삼성전자 주식회사 상황인식 리소스 핫플러그 관리 시스템 및 방법
US20210161918A1 (en) * 2018-01-10 2021-06-03 The University Of North Carolina At Chapel Hill Tigecycline for topical treatment of root canal space
CN113260407B (zh) * 2018-10-23 2023-11-14 艾比科生物医学公司 输送装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494903A (en) * 1991-10-04 1996-02-27 American Cyanamid Company 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
WO2002002095A2 (en) * 2000-06-30 2002-01-10 Pharmacia & Upjohn Company Compositions for treating bacterial infections containing oxazolidinone compound, sulbactam and an ampicillin
KR20080085184A (ko) * 2005-12-22 2008-09-23 와이어쓰 티게사이클린을 사용한 위장관 감염의 치료방법

Also Published As

Publication number Publication date
US20060251705A1 (en) 2006-11-09
NO20075690L (no) 2008-01-31
EP1877064A2 (en) 2008-01-16
WO2006121713A3 (en) 2007-03-22
AU2006244588A1 (en) 2006-11-16
RU2007140956A (ru) 2009-06-20
MX2007013895A (es) 2008-01-28
BRPI0611070A2 (pt) 2010-08-03
CN101171016A (zh) 2008-04-30
KR20080005599A (ko) 2008-01-14
CA2607143A1 (en) 2006-11-16
JP2008540431A (ja) 2008-11-20
ZA200709510B (en) 2008-11-26
WO2006121713A2 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
MX2014000292A (es) Usos de inhibidores etiquetados hsp90.
EP2128659A4 (en) TRANSPARENT FORM BODY AND REFLECTION PREVENTION ARTICLE THEREWITH
CR20110198A (es) Fijación de modo en el dominio de fourier
TWD144028S1 (zh) 吸頂燈
CR9014A (es) Novedosos derivados de heteroarilsulfamida benzofusionados como agentes anticonvulsionantes
CL2008002185A1 (es) Compuestos derivados de pirimidina, inhibidores de fosfatidilinositol-3-cinasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades resapiratorias, alergias, inflamacion, cancer, entre otras enfermedades.
EP2237792A4 (en) ANTI-C35 ANTIBODY COMBINATION THERAPIES AND METHOD
TWD144229S1 (zh) 吸頂燈
BR112014011481A2 (pt) hidrolisado de colágeno e seu uso
AR090315A1 (es) Uso de antitrombina en el tratamiento de pre-eclampsia
BR112014007150A2 (pt) artigos abrasivos de redução de ruído
AR087094A1 (es) Formulaciones que estabilizan proteinas
UY33219A (es) Cetoenoles cíclicos para terapias
CR9491A (es) Delivery of tigecycline in the presence of heparin
CL2007003020A1 (es) Metodos para proporcionar nutricion prolongada a un paciente con cancer.
TWD143838S1 (zh) 吸頂燈
PH12013500392A1 (en) Theobromine in combination with an expectorant or a mucolytic for use in therapy
TWD144040S1 (zh) 吸頂燈
DOP2010000361A (es) Dronedarona para la prevencion de la cardioversion
GT200500266A (es) Nuevos derivados de pirimidina y su uso
CO6551745A2 (es) Combinación de fármacos con teobromina y su uso en terapia
UY33662A (es) Combinaciones que comprenden inhibidores de dhodh e inhibidores de cox
TWD144844S1 (zh) 燈具
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.
CR9484A (es) Suministro de tigeciclina en la presencia de warfarina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)